Maggie Flanagan LeFlore, Ph.D.

Managing Director, MedImmune Ventures, Inc.

Maggie joined MedImmune Ventures as a Managing Director in 2007. Also within the AstraZeneca Group she served as Head of R&D Ventures 2005 to 2007, where she was on assignment to Advent International working with the Healthcare and Life Sciences venture capital investment team, and the Global Alliance Director for Global Sciences and Information from 2001 to 2005, where she led an international group responsible for evaluation, negotiation and management of global technology platform collaborations. Prior to 2001, Maggie held business development and scientific management positions at Hybridon, Inc. (1997-2000); Oncogene Science Inc. (1994-1996); and Merrell Dow Pharmaceuticals (1985-1994). Originally trained as a biophysical chemist, with a B.S. in Chemistry from the University of Kansas, and a Ph.D. in Physical Chemistry from Indiana University, she trained in molecular and cellular biology as a post-doctoral fellow at the National Institutes of Health. Maggie is currently a director of Catabasis Pharmaceuticals, Inc., Inotek Pharmaceuticals, Inc., NKT Therapeutics, Inc., and VentiRx Pharmaceuticals, Inc. and a board observer for BrainCells, Inc., Rib-X Pharmaceuticals, Inc. and Xencor, Inc.